Biotech Advances Potential 'Billion-Dollar Drug' with New Trial Launch in China
Source: Streetwise Reports
December 7, 2017 (Investorideas.com Newswire) Maxim Group analyst Jason Kolbert discussed what the launch of a clinical trial in China means for this developer of immuno-oncology therapies.
In a Nov. 30 research note, Maxim analyst Jason Kolbert reported that BeyondSpring Pharmaceuticals Inc. (BYSI:NASDAQ) strengthened its "foothold" in China with the launch of a Phase 2/3 clinical trial of its small molecule plinabulin, which offers "chemotherapy-induced neutropenia prevention, anti-cancer efficacy and immune-related side effect reduction with a favorable adverse event profile."
Study 106, led by co-principal investigator Dr. Qingyuan Zhang, began enrollment on Nov. 29 at the Harbin Medical University Cancer Hospital. Participants are patients who receive combination chemotherapy of taxotere, doxorubicin and cyclophosphamide, as it often causes severe neutropenia. The trial aims to "demonstrate plinabulin's superiority compared with Neulasta" in this population, noted Kolbert.
Other plinabulin studies underway are in individuals with non-small cell lung cancer. They include a Phase 3 trial in the U.S. and China with the chemotherapy agent docetaxel and a Phase 1 study in the U.S. with the PD-1 antibody nivolumab. Plinabulin, wrote Kolbert, has "the potential to become the new standard of care for chemotherapy patients across multiple indications."
The analyst added that "a significant opportunity in China" exists for plinabulin for those two indications alone: chemotherapy-induced neutropenia and non-small cell lung cancer. China is home to more than 4 million people with cancer, lung cancer being the most common. The therapeutic could "create a new therapy paradigm in the large oncology markets now opening in China, which is not at all reflected in the company's current valuation, in our opinion," Kolbert indicated.
Maxim estimates approvals and launch of plinabulin in China by 2020. Recently enacted regulatory reforms there could mean "an accelerated review (shorter time to the marketplace)" for plinabulin, Kolbert deduced. Further, "based on historical, high approval rates of oncology drugs developed by Chinese companies, there is higher probability for plinabulin to succeed in obtaining market approval by the China Food and Drug Administration."
As for the potential overall market for plinabulin, it "extends beyond the $8 billion ($8B) biologics market and could be upwards of $30B," estimated Kolbert. "As such, plinabulin, even conservatively, should be a billion-dollar drug, which points to upside at the current valuation."
BeyondSpring is currently trading at around $31.59 per share versus Maxim's $52 per share target price on it, which it rates a Buy.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire http://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.